Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by JayjayUSA12007on Sep 05, 2018 12:00am
216 Views
Post# 28563354

RE:RE:RE:RE:RE:So what about Fuzeon’s MDR patients ?

RE:RE:RE:RE:RE:So what about Fuzeon’s MDR patients ?
Quote:"...He believes the doctors will be able to control their patients viral events using other oral drugs without having to resort to Trogarzo. Time will tell if that is true but it might be. It is one of the big outstanding questions that we have not been able to answer - to what extent will the doctors turn to Trogarzo versus continuing to tweak the other oral drugs, including new higher line HIV drugs that will be coming along, availale to their MDR patients..."

Is it NOT true that Thera/Taimed already researched on MDR patient population and found that every year approximately 10,000 to 15,000 patients would fail existing treatment ? Wouldn't that research render the above speculation (i.e. gut feelings) moot ?
Bullboard Posts